News

Filter

Current filters:

Roche

226 to 235 of 97221 results

FDA accepts NDA filing from AstraZeneca for Iressa

FDA accepts NDA filing from AstraZeneca for Iressa

02-12-2014

The US Food and Drug Administration has accepted for filing the New Drug Application from Iressa (gefitinib)…

AstraZenecaIressaOncologyPharmaceuticalRegulationUK

Pozen shares slide as gastric ulcer collaboration with Sanofi ends

Pozen shares slide as gastric ulcer collaboration with Sanofi ends

02-12-2014

French drug major Sanofi and North Carolina-based pharma company Pozen have agreed to end their collaboration…

FranceGastro-intestinalsLicensingPA8140/PA32540PharmaceuticalPozenSanofiUSA

Exelixis’ cabozantinib fails to meet primary endpoint in Phase III prostate cancer trial

Exelixis’ cabozantinib fails to meet primary endpoint in Phase III prostate cancer trial

02-12-2014

US biotech firm Exelixis has announced top-line results from the final analysis of COMET-2, a randomized,…

cabozantinibExelixisOncologyPharmaceuticalResearchUSA

Otsuka acquires Avanir for $3.5 billion

Otsuka acquires Avanir for $3.5 billion

02-12-2014

The US subsidiary of Japanese drug maker Otsuka has acquired US CNS specialist Avanir Pharmaceuticals…

AvanirJapanMergers & AcquisitionsNeurologicalNuedextaOtsuka PharmaceuticalPharmaceuticalUSA

NICE reverses October decision and approves Roche's Gazyvaro

NICE reverses October decision and approves Roche's Gazyvaro

02-12-2014

The UK’s National Institute for Health and Care Excellence (NICE) has reversed its decision on Gazyvaro…

GazyvaroOncologyPharmaceuticalRegulationRocheUK

Medical Research Council develops XNAzyme, a world-first synthetic enzyme

Medical Research Council develops XNAzyme, a world-first synthetic enzyme

01-12-2014

Scientists from the UK's Medical Research Council have created the world’s first artificial enzymes…

BiotechnologyChemistryGeneticsMedical Research CouncilResearchUK

Novartis’ fingolimod fails to meet endpoint in primary progressive multiple sclerosis study

Novartis’ fingolimod fails to meet endpoint in primary progressive multiple sclerosis study

01-12-2014

Swiss drug major Novartis’ has announced that its Phase III INFORMS study in primary progressive multiple…

CNS DiseasesfingolimodGilenyaNovartisPharmaceuticalResearchSwitzerland

Two batches of Novartis' Fluad taken off market for investigation in Italy after 13 deaths

Two batches of Novartis' Fluad taken off market for investigation in Italy after 13 deaths

01-12-2014

The Italian Medicines Agency (AIFA) has suspended two batches of Swiss drug major Novartis’ Fluad seasonal…

Anti-viralsFluadItalian Medicines AgencyItalyNovartisPharmaceuticalRegulation

Sources say GSK to cut hundreds of jobs in the US following oncology business sale to Novartis

Sources say GSK to cut hundreds of jobs in the US following oncology business sale to Novartis

01-12-2014

Sources close to the company have said UK pharma major GlaxoSmithKline is to announce hundreds of job…

AdvairGSKOncologyPharmaceuticalProductionSocial IssuesUSA

226 to 235 of 97221 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top